Breaking News & Top Stories
A significant shortage of estrogen patches is affecting women across the United States who are seeking hormone replacement therapy (HRT) to manage symptoms of perimenopause and menopause. The demand for…
Boulder-based Enveda Biosciences has received clearance from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for its drug candidate, ENV-6946, aimed at treating inflammatory bowel disease (IBD).…
Efforts to combat the opioid overdose crisis in Colorado are gaining momentum as residents increasingly purchase naloxone, an overdose-reversal drug, now available over the counter. Since September 2023, when the…
Biotech investors can expect a significant shift in the market landscape in 2026, according to industry expert Bruce Booth, a partner at Atlas Venture. His insights indicate that after two…
A significant advancement in the fight against drug-resistant infections emerged last week with the approval of two new oral antibiotics by the U.S. Food and Drug Administration (FDA). Among them…
The U.S. Food and Drug Administration (FDA) has approved a daily pill designed to enhance libido among postmenopausal women, extending access to those up to the age of 65. This…
The U.S. Food and Drug Administration (FDA) has expanded the approval of the libido-boosting drug Addyi, allowing its use for women over the age of 65 who have undergone menopause.…
Hereditary angioedema (HAE), a rare genetic condition characterized by recurrent and unpredictable swelling attacks, is receiving unprecedented attention in 2025 due to the rapid approval of three new treatments by…
The U.S. Food and Drug Administration (FDA) reported that over 2,500 medical device recalls are issued annually in the United States. These recalls can range from simple inspections to the…
The competition for Metsera’s PD-(L)1xVEGF bispecific therapy has intensified, prompting significant interest from major pharmaceutical companies. This race represents a critical moment in the development of innovative cancer treatments, as…